Claims
- 1. A method of diagnosing or evaluating a skin injury or condition affecting the skin, said method comprising evaluating expression of:
a) a chemokine selected from MCP-2 (CCL8), DC-CK1 (CCL18), TARC (CCL17), RANTES (CCL5), MIP3b (CCL19), I-309 (CCL1), MIG (CXCL9), IP-10 (CXCL10), ITAC (CXCL11), BCA-1 (CXCL13), lymphotactin (XCL1), MDC (CCL22), IL-8 (CXCL8), MCP-3 (CCL7), SDF-1, or MCP-1 (CCL2); or b) a chemokine receptor selected from CCR5, CCR7, CXCR3, CXCR5, XCR1, CCR2, CCR4, CCR8, or CXCR4.
- 2. The method of claim 1, wherein said condition is selected from lupus erythematosus, atopic dermatitis, cutaneous wound, skin healing, or an inflammatory condition.
- 3. The method of claim 1, wherein said evaluating is:
a) measuring a plurality of said expression levels; b) measuring mRNA levels; or c) measuring protein levels.
- 4. A method of treating a condition affecting the skin, said method comprising administering an antagonist of:
a) a chemokine selected from MCP-2 (CCL8), DC-CK1 (CCL18), TARC (CCL17), RANTES (CCL5), MIP3b (CCL19), I-309 (CCL1), MIG (CCL9), IP-10 (CXCL10), ITAC (CXCL11), BCA-1 (CXCL13), lymphotactin (XCL1), MDC (CCL22), IL-8 (CXCL8), MCP-3 (CCL7), or MCP-1 (CCL2); or b) a chemokine receptor selected from CCR5, CCR7, CXCR3, CXCR5, XCR1, CCR2, CCR4, CCR8, or CXCR4.
- 5. The method of claim 4, wherein said administering is:
a) a plurality of said antagonists; or b) in combination with another therapeutic.
- 6. The method of claim 4, wherein said antagonist is an antibody which prevents interaction of:
a) said chemokine with its receptor, or b) said chemokine receptor with its ligand.
- 7. The method of claim 4, wherein said treating is preventative.
- 8. The method of claim 4, wherein said condition is lupus erythematosus, and said antagonist is of:
a) a chemokine selected from MCP-2 (CCL8), RANTES (CCL5), MIP3b (CCL19), MIG (CXCL9), IP-10 (CXCL10); ITAC (CXCL11); BCA-1 (CXCL13), or lymphotactin (XCL1); or b) a chemokine receptor selected from CCR5, CCR7, CXCR3, CXCR5, or XCR1.
- 9. The method of claim 4, wherein said condition is atopic dermatitis, and said antagonist is of:
a) a chemokine selected from DC-CK1 (CCL18), TARC (CCL17), I-309 (CCL1), MDC (CCL22), IP-10 (CXCL10), MIG (CXCL9), or ITAC (CXCL11); or b) a CCR2, CCR3, CCR4, or CCR8 chemokine receptor.
- 10. A method of accelerating wound healing comprising administering to an individual suffering from a wound a chemokine selected from lymphotactin (XCL1), IL-8 (CXCL8), MCP3 (CCL7), MCP1 (CCL2), MCP2 (CCL8), RANTES (CCL5), MIG (CXCL9), or SDF-1.
- 11. The method claim 8, wherein said administering is:
a) a plurality of said chemokines; b) in combination with another therapeutic; or c) by expression of a nucleic acid.
- 12. The method of claim 8, wherein said healing is from skin loss from burn.
Parent Case Info
[0001] This application claims benefit of U.S. Provisional Patent Application No. 60/250,782, filed Dec. 1, 2000.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60250782 |
Dec 2000 |
US |